Patent · US Active

Compositions and methods for treating CDK4/6-mediated cancer

US11541051B2 · kind B2 · utility

1Cited by

5References

15Claims

0Family size

Assignee

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

Jian Jin · Suzhou, CN
Xiaobao Yang · New York, US
Jing Liu · San Diego, US
Yan Xiong · New York, US
Poulikos Poulikakos · New York, US
Zoi Karoulia · New York, US
Xuewei Wu · Beijing, CN
Tamer Ahmed · Edison, US

Key dates

Filing date	Dec 7, 2017
Grant date	Jan 3, 2023
Priority date	—
Expiry date	Dec 7, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y203/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods for designing heterobifunctional small molecules which selectively degrade/disrupt CDK4/6 and compositions and methods of using such degraders/disruptors to treat CDK4/6-mediated cancer are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.